Aridis Announces a Key Milestone of Closing of Patient Enrollment in the Phase IIa Study of AR-501 in Cystic Fibrosis Patients

Aridis Pharmaceuticals, Inc. announced the closing of patient enrollment in the multiple ascending dose and dose-ranging cohorts in the Phase IIa clinical trial of AR-501 in cystic fibrosis patients.